Research and Markets: Lung Cancer Drug Pipeline Update 2013: Non-Small Cell Lung Cancer and Small Cell Lung Cancer Comprises Over 95% of all Lung Cancers High unmet needs still persist for this tumor type and despite two decades of extensive R&D and chemotherapy use, the median overall survival of NSCLC patient’s remains below 12 months.
